Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 35 clinical trials
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

carboplatin
lung cancer
tumor cells
adenocarcinoma
metastasis
  • 1154 views
  • 28 Jun, 2022
  • 1035 locations
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study

This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and …

platelet count
carboplatin
pemetrexed
neutrophil count
paclitaxel
  • 136 views
  • 17 Jun, 2022
  • 460 locations
AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

The purpose of this study is to find out what effects (good and bad) AZD1775 used in combination with carboplatin and paclitaxel will have on participants and their cancer.

lung carcinoma
carboplatin
lung cancer
paclitaxel
carboplatin/paclitaxel
  • 2 views
  • 24 Mar, 2022
  • 2 locations
Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung

antibody (bsAb) with PSMAxCD3 specificity developed within DKTK. CC-1 binds to human prostate-specific membrane antigen (PSMA) on tumor cells of squamous cell carcinoma of the lung (SCC) as well as to

  • 0 views
  • 25 Mar, 2022
Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma

Tislelizumab combined with chemotherapy has shown good efficacy and safety in clinical studies of lung adenocarcinoma (RATIONALE 304) and lung squamous cell carcinoma (RATIONALE 307), thus has

  • 0 views
  • 03 Sep, 2021
  • 1 location
Electrocautery Ablation for the Prevention of Lung Cancer (EARL)

This study evaluates whether EC treatment is effective in delaying the progression of high-grade lung lesion(s) to invasive lung cancer. Participants will be randomised to receive either electrocautery (EC) treatment with bronchoscopy surveillance (=intervention), or bronchoscopy surveillance alone (=control) in a 2:1 ratio.

  • 0 views
  • 04 May, 2022
  • 1 location
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

This is a first-in-human (FIH), Phase 1, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in subjects with glypican-3 positive (GPC3+) advanced solid tumors.

  • 0 views
  • 25 May, 2022
  • 1 location
The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy

This protocol pertains specifically to the prospective lung squamous cell carcinoma pre-malignant lesion (PML) cohort that will form a primary study group for the Lung Pre-Cancer Atlas.

sputum cytology
lung cancer
cancer
lung carcinoma
withdrawn
  • 0 views
  • 18 Feb, 2022
  • 2 locations
Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC

treatment with Camrelizumab and Endo in advanced lung squamous cell carcinoma

cancer chemotherapy
squamous non-small cell lung cancer
neutrophil count
ct scan
squamous cell carcinoma
  • 0 views
  • 01 Mar, 2022
  • 1 location
PD1 and PARP for Maintenance Therapy in NSLLC

PARP inhibitor and PD1 in lung squamous cell carcinoma The current study will compare PD1 plus maintenance PARP for the treatment of squamous NSCLC. The study's 2 primary hypotheses are: respect

  • 0 views
  • 06 Jun, 2022
  • 1 location